Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 9 |
| List of Tables | 9 | 1 |
| List of Figures | 10 | 1 |
| Introduction | 11 | 1 |
| Global Markets Direct Report Coverage | 11 | 1 |
| Relapsed Chronic Lymphocytic Leukemia (CLL) Overview | 12 | 1 |
| Therapeutics Development | 13 | 2 |
| Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) Overview | 13 | 1 |
| Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) Comparative Analysis | 14 | 1 |
| Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics under Development by Companies | 15 | 2 |
| Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics under Investigation by Universities/Institutes | 17 | 1 |
| Relapsed Chronic Lymphocytic Leukemia (CLL) Pipeline Products Glance | 18 | 3 |
| Late Stage Products | 18 | 1 |
| Clinical Stage Products | 19 | 1 |
| Early Stage Products | 20 | 1 |
| Relapsed Chronic Lymphocytic Leukemia (CLL) Products under Development by Companies | 21 | 3 |
| Relapsed Chronic Lymphocytic Leukemia (CLL) Products under Investigation by Universities/Institutes | 24 | 1 |
| Relapsed Chronic Lymphocytic Leukemia (CLL) Companies Involved in Therapeutics Development | 25 | 32 |
| 4SC AG | 25 | 1 |
| AbbVie Inc | 26 | 1 |
| Aptevo Therapeutics Inc | 27 | 1 |
| Astellas Pharma Inc. | 28 | 1 |
| Astex Pharmaceuticals Inc | 29 | 1 |
| Boehringer Ingelheim GmbH | 30 | 1 |
| Bristol-Myers Squibb Company | 31 | 1 |
| Celgene Corporation | 32 | 1 |
| Cellular Biomedicine Group, Inc. | 33 | 1 |
| Cyclacel Pharmaceuticals, Inc. | 34 | 1 |
| F. Hoffmann-La Roche Ltd. | 35 | 1 |
| Gilead Sciences, Inc. | 36 | 1 |
| Hutchison MediPharma Limited | 37 | 1 |
| ImmunoGen, Inc. | 38 | 1 |
| Immunomedics, Inc. | 39 | 1 |
| Incyte Corporation | 40 | 1 |
| Innate Pharma S.A. | 41 | 1 |
| Juno Therapeutics Inc. | 42 | 1 |
| Karyopharm Therapeutics, Inc. | 43 | 1 |
| LFB S.A. | 44 | 1 |
| Lymphocyte Activation Technologies, S.A. | 45 | 1 |
| Millennium Pharmaceuticals Inc | 46 | 1 |
| MorphoSys AG | 47 | 1 |
| Novartis AG | 48 | 1 |
| Oncternal Therapeutics, Inc. | 49 | 1 |
| Ono Pharmaceutical Co., Ltd. | 50 | 1 |
| PIQUR Therapeutics AG | 51 | 1 |
| Rhizen Pharmaceuticals S.A. | 52 | 1 |
| Sanofi | 53 | 1 |
| TRACON Pharmaceuticals Inc | 54 | 1 |
| Tragara Pharmaceuticals, Inc. | 55 | 1 |
| Verastem, Inc. | 56 | 1 |
| Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Assessment | 57 | 12 |
| Assessment by Monotherapy Products | 57 | 1 |
| Assessment by Combination Products | 58 | 1 |
| Assessment by Target | 59 | 3 |
| Assessment by Mechanism of Action | 62 | 3 |
| Assessment by Route of Administration | 65 | 2 |
| Assessment by Molecule Type | 67 | 2 |
| Drug Profiles | 69 | 209 |
| (dezapelisib + itacitinib adipate) Drug Profile | 69 | 1 |
| 4SC-202 Drug Profile | 70 | 2 |
| acalabrutinib Drug Profile | 72 | 3 |
| ACP-319 Drug Profile | 75 | 1 |
| afuresertib hydrochloride Drug Profile | 76 | 3 |
| AGS-67E Drug Profile | 79 | 2 |
| AT-7519 Drug Profile | 81 | 3 |
| atezolizumab Drug Profile | 84 | 14 |
| BI-836826 Drug Profile | 98 | 2 |
| BMS-986016 Drug Profile | 100 | 2 |
| buparlisib hydrochloride Drug Profile | 102 | 5 |
| CBM-C19.1 Drug Profile | 107 | 1 |
| CC-122 Drug Profile | 108 | 2 |
| Cellular Immunotherapy for Chronic Lymphocytic Leukaemia Drug Profile | 110 | 1 |
| Cellular Immunotherapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia Drug Profile | 111 | 1 |
| duvelisib Drug Profile | 112 | 11 |
| HMPL-523 Drug Profile | 123 | 2 |
| idelalisib Drug Profile | 125 | 8 |
| IMGN-529 Drug Profile | 133 | 2 |
| IMMU-114 Drug Profile | 135 | 2 |
| JCAR-014 Drug Profile | 137 | 3 |
| JCAR-015 Drug Profile | 140 | 5 |
| lirilumab Drug Profile | 145 | 4 |
| monalizumab Drug Profile | 149 | 3 |
| MOR-208 Drug Profile | 152 | 5 |
| nivolumab Drug Profile | 157 | 29 |
| obinutuzumab Drug Profile | 186 | 7 |
| ofatumumab Drug Profile | 193 | 8 |
| otlertuzumab Drug Profile | 201 | 3 |
| PCAR-019 Drug Profile | 204 | 1 |
| PCAR-119 Drug Profile | 205 | 1 |
| pilaralisib Drug Profile | 206 | 2 |
| PNK-007 Drug Profile | 208 | 1 |
| PQR-309 Drug Profile | 209 | 2 |
| S-055746 Drug Profile | 211 | 1 |
| sapacitabine Drug Profile | 212 | 6 |
| selinexor Drug Profile | 218 | 19 |
| spebrutinib besylate Drug Profile | 237 | 2 |
| TAK-659 Drug Profile | 239 | 1 |
| TG-02 Drug Profile | 240 | 3 |
| TGR-1202 Drug Profile | 243 | 7 |
| tisagenlecleucel-T Drug Profile | 250 | 5 |
| TRC-102 Drug Profile | 255 | 2 |
| ublituximab Drug Profile | 257 | 7 |
| UC-961 Drug Profile | 264 | 2 |
| ulocuplumab Drug Profile | 266 | 1 |
| urelumab Drug Profile | 267 | 2 |
| venetoclax Drug Profile | 269 | 9 |
| Relapsed Chronic Lymphocytic Leukemia (CLL) Dormant Projects | 278 | 2 |
| Relapsed Chronic Lymphocytic Leukemia (CLL) Discontinued Products | 280 | 1 |
| Relapsed Chronic Lymphocytic Leukemia (CLL) Product Development Milestones | 281 | 12 |
| Featured News &Press Releases | 281 | 1 |
| Oct 13, 2016: TG Therapeutics Announces the Launch of the Phase 1/2 Study of TGR-1202 and Carfilzomib in Patients with Relapsed or Refractory Lymphoma | 281 | 1 |
| May 18, 2016: AbbVie To Present Data on Venclexta (venetoclax) at ASCO 2016 | 282 | 1 |
| Mar 17, 2016: Information Update - International clinical trials, including trials in Canada, are being stopped due to serious adverse events with the drug Zydelig, in combination with other cancer drugs | 282 | 1 |
| Jan 20, 2016: Abbvie's Venetoclax Receives Breakthrough Therapy Designation From FDA In Combination With Rituximab For The Treatment Of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia | 283 | 1 |
| Dec 07, 2015: Acerta Pharma Announces Study Published in New England Journal of Medicine Demonstrates Acalabrutinib (ACP-196) Shows Marked Activity in Relapsed Chronic Lymphocytic Leukemia | 283 | 1 |
| Dec 07, 2015: TG Therapeutics Announces Data Presentation for TGR-1202 in Combination With Ibrutinib at the 57th American Society of Hematology Annual Meeting | 284 | 1 |
| Nov 05, 2015: Genentech to Present New Clinical Data From Venetoclax at American Society of Hematology 2015 Annual Meeting | 285 | 1 |
| Jun 12, 2015: Phase 1b Study of Investigational Treatment Venetoclax With Rituximab Shows Clinical Response in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia | 286 | 1 |
| Jun 11, 2015: TG Therapeutics to Present Clinical Data on TG-1101 in combination with ibrutinib at the 20th Congress of the European Hematology Association and the 13th International Congress on Malignant Lymphoma | 287 | 1 |
| May 11, 2015: Abbvie To Present New Data From Studies Of Duvelisib Assets In Multiple Cancers At The 51st American Society Of Clinical Oncology Annual Meeting | 288 | 1 |
| May 06, 2015: Investigational Medicine Venetoclax Receives Breakthrough Therapy Designation In Relapsed Or Refractory Chronic Lymphocytic Leukemia In Previously Treated Patients With The 17P Deletion Genetic Mutation | 288 | 1 |
| Dec 05, 2014: Roche to present clinical data on obinutuzumab at ASH | 289 | 1 |
| Nov 06, 2014: Infinity Announces Clinical and Preclincal Data for Duvelisib to Be Presented at ASH 2014 Annual Meeting | 289 | 2 |
| Jul 25, 2014: Zydelig (idelalisib) approved by the FDA, available at Biologics | 291 | 1 |
| Jul 23, 2014: U.S. Food and Drug Administration Approves Gilead s Zydelig (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma | 291 | 2 |
| Appendix | 293 | 2 |
| Methodology | 293 | 1 |
| Coverage | 293 | 1 |
| Secondary Research | 293 | 1 |
| Primary Research | 293 | 1 |
| Expert Panel Validation | 293 | 1 |
| Contact Us | 293 | 1 |
| Disclaimer | 294 | 1 |
